2020 年 12 月 10 日
LA JOLLA—The Salk Institute is excited to welcome Assistant Professor Christina Towers, a top researcher in the field of cancer biology. Towers will join Salk’s renowned NCI-designated Cancer Center to examine how cancer cells recycle both their own nutrients and the power-generating structures called mitochondria in order to survive. Her long-term goal is to improve the treatment options for cancer patients.

点击此处 用于高分辨率图像。.
Credit: Bekah Broas/BLB Photography
“Christina is an innovative cancer researcher who is taking novel approaches to understand the biological basis of cancer,” says Salk President 鲁斯蒂·盖奇. “Although she is an early-career scientist, Christina is already an accomplished researcher in her field, and we are thrilled to have her join the Salk faculty.”
Ongoing clinical trials have repeatedly shown that tumor cells can adapt to cancer-fighting medications, which leads to a recurrence of the cancer. Towers is using a combination of gene-editing techniques, light-based genetic manipulation (optogenetics), three-dimensional miniature organs (“organoids”), and detailed imaging to identify the best ways to target the recycling pathways that cancer cells use to adapt and survive. Her results will hopefully lead to new targeted cancer therapies that can improve patient outcomes and survival.
“Christina is a creative dynamo unafraid to ask big biological questions that will lead to new breakthroughs in cancer. Her research fits perfectly with the strengths of the Salk Cancer Center, and we are excited to see her future successes,” says Salk Cancer Center Director 鲁本-肖.
Towers joins Salk from the University of Colorado Denver Anschutz Medical Campus, where she was a postdoctoral fellow in the lab of Andrew Thorburn. She holds numerous awards including the Outstanding Dissertation Award for her PhD in molecular biology from the University of Colorado, the Pathway to Independence K99/R00 award, the Cancer League of Colorado Pilot Award, the American Cancer Society Postdoctoral Fellowship, two NRSA NIH T32 awards, the UNCF/Merck Graduate Science Research Dissertation Fellowship, the NIH R0-1 Diversity Supplement Graduate Fellowship, three UC Department of Pharmacology Excellence in Research Awards, along with many others.
The BioMed Realty Management Team has announced that it will match up to $1 million to fund Towers’ recruitment and to support her research and that of the Salk Cancer Center. BioMed’s president and CEO, Tim Schoen, is a Salk trustee and chairman of the Institute’s 攻克癌症倡议 Advisory Committee.
宣传办公室
电话:(858) 453-4100
press@salk.edu
萨尔克研究所是一个独立的非营利性研究机构,由首个安全有效的脊髓灰质炎疫苗的研发者乔纳斯·索尔克于1960年创立。该研究所的使命是推动以合作、敢于冒险为特点的基础性研究,以应对癌症、阿尔茨海默病和农业脆弱性等社会最紧迫的挑战。这项基础科学支撑着所有的转化研究,产生有助于全球新药和创新的见解。.